perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1 Long term anti-SARS-CoV-2 antibody kinetics and correlate of

2 protection against Omicron BA.1/BA.2 infection

3

Javier Perez-Saez^{1,2,*}, María-Eugenia Zaballa¹, Julien Lamour¹, Sabine Yerly³, Richard
Dubos¹, Delphine Courvoisier⁴, Jennifer Villers¹, Jean-François Balavoine⁵, Didier Pittet^{5,6},
Omar Kherad^{5,7}, Nicolas Vuilleumier^{3,5}, Laurent Kaiser^{3,5,8,9}, Idris Guessous^{10,11#}, Silvia
Stringhini^{1,12#}, Andrew S. Azman^{1,2#} on behalf of the Specchio-COVID19 study group

8

9 1 Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals,

- 10 Geneva, Switzerland
- 11 2 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
- 12 United States

13 3 Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva,

- 14 Switzerland
- 15 4 General Directorate of Health, Geneva, Switzerland
- 16 5 Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- 17 6 Infection Control Program and World Health Organization Collaborating Centre on Patient Safety,
- 18 Geneva University Hospitals, Geneva, Switzerland
- 19 7 Division of Internal Medicine, Hôpital de la Tour, Geneva, Switzerland
- 20 8 Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Geneva,
- 21 Switzerland
- 22 9 Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland
- 23 10 Department of Health and Community Medicine, Faculty of Medicine, University of Geneva,24 Geneva, Switzerland
- 25 11 Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva,
 26 Switzerland
- 27 12 University Centre for General Medicine and Public Health, University of Lausanne, Lausanne,
- 28 Switzerland
- 29
- 30 [#]Equal contribution
- 31 * Corresponding author: javier.perez@hcuge.ch

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 Abstract

33 Binding antibody levels against SARS-CoV-2 have shown to be correlates of protection 34 against infection with pre-Omicron lineages. This has been challenged by the emergence of immune-evasive variants, notably the Omicron sublineages, in an evolving immune 35 36 landscape with high levels of cumulative incidence and vaccination coverage. This in turn 37 limits the use of commercially available high-throughput methods to quantify binding 38 antibodies as a tool to monitor protection at the population-level. In this work, we leverage 39 repeated serological measurements between April 2020 and December 2021 on 1'083 40 participants of a population-based cohort in Geneva, Switzerland, to evaluate anti-Spike 41 RBD antibody levels as a correlate of protection against Omicron BA.1/BA.2 infections 42 during the December 2021-March 2022 epidemic wave. We do so by first modeling antibody 43 dynamics in time with kinetic models. We then use these models to predict antibody 44 trajectories into the time period where Omicron BA.1/BA.2 were the predominant circulating 45 sub-lineages and use survival analyses to compare the hazard of having a positive SARS-46 CoV-2 test by antibody level, vaccination status and infection history. We find that antibody 47 kinetics in our sample are mainly determined by infection and vaccination history, and to a 48 lesser extent by demographics. After controlling for age and previous infections (based on 49 anti-nucleocapsid serology), survival analyses reveal a significant reduction in the hazard of 50 having a documented positive SARS-CoV-2 infection during the Omicron BA.1/BA.2 wave 51 with increasing antibody levels, reaching up to a three-fold reduction for anti-S antibody 52 levels above 800 IU/mL (HR 0.30, 95% CI 0.22-0.41). However, we did not detect a 53 reduction in hazard among uninfected participants. Taken together these results indicate that 54 anti-Spike RBD antibody levels, as quantified by the immunoassay used in this study, are an 55 indirect correlate of protection against Omicron BA.1/BA.2 for individuals with a history of 56 previous SARS-CoV-2 infection. Despite the uncertainty in what SARS-COV-2 variant will come next, these results provide reassuring insights into the continued interpretation of 57 58 SARS-CoV-2 binding antibody measurements as an independent marker of protection at 59 both the individual and population levels.

60 Introduction

While by mid-2022 a large fraction of the global population had developed anti-SARS-CoV-2 binding antibodies through infection and/or vaccination (Bergeri et al., 2022; Zaballa et al., 2022), it remains unclear whether seroprevalence results translate into prevalence of effective protection against infection (Theel et al., 2020). Neutralizing antibodies may provide

a reliable correlate of protection against both infection and severe disease (Earle et al.,
2021; Gilbert et al., 2022; Khoury et al., 2021; Krammer, 2021). Neutralization assays are,
however, labor-intensive and challenging to use at a large scale, despite advances in highthroughput surrogate assays (Fenwick et al., 2021).

69

70 Binding antibody measurements have been found to correlate with neutralization capacity 71 against the ancestral SARS-CoV-2 strain at different degrees depending on time post 72 infection/vaccination, and on immuno-assay (Earle et al., 2021; Goldblatt et al., 2022; 73 L'Huillier et al., 2021). Evidence for their more general use as correlate of protection is 74 mounting both from population-level (Earle et al., 2021; Goldblatt et al., 2022), as well as 75 individual-level studies in the context of vaccine trials (Dimeglio et al., 2022b; Feng et al., 76 2021; Gilbert et al., 2022; Wei et al., 2021). These studies suggest that higher antibody 77 measurements after infection and/or vaccination tend to reduce subsequent infection risk 78 (Osman et al., 2021). However, most of these studies focused on the ancestral SARS-CoV-2 79 strain and it is yet to be clarified whether these results robustly extend to the Omicron 80 subvariants (Hertz et al., 2022; Zar et al., 2022).

81

82 The evaluation of binding antibody levels as correlates or protection is challenged by the 83 constant evolution of the anti-SARS-CoV-2 immune landscape through vaccination and 84 successive epidemic waves driven by different virus variants. Longitudinal antibody studies 85 up to 14 months follow-up have shown that antibody levels change with time since infection 86 and/or vaccination across individuals, and depending on the immuno-assays used for 87 detection (Eyran et al., 2022; Gallais et al., 2021; Peluso et al., 2021; Perez-Saez et al., 88 2021). Characterization of long-term antibody kinetics provides an opportunity for leveraging 89 serological cohort studies to complement vaccine trials in evaluating binding antibody levels 90 as correlate of protection against future infections. By relying on binding antibody 91 immunoassays that are simple, standardized and widely used worldwide, the results of these 92 studies have the potential to be generalized to other settings despite their functional 93 limitation. These cohort studies might therefore contribute by assessing the extension of 94 results to different commercially-available immunoassays and a wider range of 95 infection/vaccination histories, in particular to non-vaccinated individuals.

96

97 In this study, we aim to evaluate the use of a commercially available immunoassay as a 98 correlate of protection in the Omicron era. We do so by leveraging repeated serological 99 measurements and reported infections on a population-based longitudinal cohort followed for 100 up to 20 months in the state of Geneva, Switzerland. We first characterize antibody 101 dynamics during the longitudinal serology period (April 2020 to December 2021) using

kinetic models fit to observed antibody measurements. We then project each individual's antibody trajectories into the Omicron exposure period (December 2021 to March 2022) to explore the relationship between projected antibody levels and having a SARS-CoV-2 positive test.

106 Materials and methods

107 Study design

108 This study uses data from the population-based Specchio-COVID19 cohort, composed of adult participants recruited through serological surveys (Baysson et al., 2022; Stringhini et 109 110 al., 2021a, 2021b, 2020). Following their baseline serology, participants in this cohort are 111 regularly invited to complete online guestionnaires, where they report SARS-CoV-2 test 112 results, disease severity and vaccination status, and can be proposed one or several 113 serological tests during the follow-up. Each participant coming for a follow-up serology provided a venous blood sample and filled in a short paper questionnaire on site to 114 115 update/complete their information on infection and vaccination statuses.

116

117 In this study, our main analysis consisted of two steps. Firstly, we analyzed antibody 118 trajectories during the longitudinal serology period, when serological testing follow-up was conducted (April 6th 2020, to December 17th 2021). Secondly, we evaluated correlates of 119 120 protection against infection during the "exposure period", using information on SARS-CoV-2 121 infections from the surge of the Omicron BA.1 subvariant in the state of Geneva until the end of the study period (December 25th 2021 to March 20th 2022) (Figure 1). In this period there 122 123 were no specific guarantine and isolation measures following SARS-CoV-2 infection nor 124 other specific recommendations in Geneva, which may have contributed to low virological 125 testing rates. During the exposure period Omicron BA.1 and BA.2 subvariants comprised 126 nearly all infections. From all participants of the Specchio-COVID19 cohort, in this analysis, we only included those having at least two positive serologies and for whom we had 127 complete vaccination information by March 20th 2022 (Supplementary Material Figure S1). 128 129 During the study period, the only available COVID-19 vaccines in Switzerland were the 130 mRNA-BNT162b2/Comirnaty from Pfizer/BioNTech (since December 2020), mRNA-1273 131 from Moderna/US NIAID (since January 2021), and the Janssen Ad26.COV2.S COVID-19 132 vaccine (since October 2021).

This study was approved by the Geneva Cantonal Commission for Research Ethics (CCER
project number 2020-00881) and written informed consent was obtained from all
participants.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.13.22283400; this version posted December 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Immunoassays 136

137 For this study, we used the quantitative Elecsys anti-SARS-CoV-2 RBD immunoassay, 138 which measures total antibodies (IgG/A/M) against the receptor binding domain of the virus 139 spike (S) protein (#09 289 275 190, Roche-S, Roche Diagnostics, Rotkreuz, Switzerland). 140 Seropositivity was defined using the cut-off provided by the manufacturer of ≥ 0.8 U/mL. 141 Output test values were transformed to WHO international standard units by multiplying by a 142 factor of 1.184. We calculated the intra-lot coefficient of variation (CV) for each batch of our 143 internal positive control serum and the maximum CV (7.3%) was used to define uncertainty 144 in serological measurements in the kinetic model described below (Supplementary Material 145 Section S2). To identify past infections in vaccinated participants, we also measured total

146 levels of antibodies binding the nucleocapsid (N) protein using the semiquantitative Elecsys 147 anti-SARS-CoV-2 N immunoassay (#09 203 079 190, Roche-N). The three vaccines 148 available in Switzerland during the study period elicit a response exclusively to the Spike 149 protein of SARS-CoV-2, as opposed to infection, typically eliciting a response to both the N 150 and S virus proteins. Although not the focus of the main analysis, we also present anti-N 151 antibody trajectories in the Supplementary Material (Supplementary Material Section S3).

152 SARS-CoV-2 virological tests data

For the correlate of protection analysis, results of PCR and antigenic tests were extracted from the ARGOS database up to March 20th 2022. The ARGOS database consists of a general register of COVID-19 diagnostic tests performed in the state of Geneva since February 2020 and is maintained by the state directorate for health (Genecand et al., 2021). Data on test results from ARGOS were supplemented with additional information on COVID-19 diagnostic tests (PCR or antigen-based rapid diagnostic tests [RDTs] including self-tests) as self-reported by the participants through regular questionnaires.

160 Statistical analyses

Antibody trajectories analysis. In the first step of the analysis ("longitudinal serology" 161 162 period in Figure 1), we characterized antibody dynamics by fitting the observed antibody 163 trajectories to bi-phasic kinetic models (Pelleau et al., 2021). These models assume an initial 164 post-infection/vaccination antibody boost (increase in antibody levels at a given time postexposure) followed by initially fast then slower exponential decay. We here expanded these 165 models to account for multiple boosting events due to infection and/or vaccination. The size 166 167 of antibody boosts and decay in time are determined by age, sex and boosting history (the 168 sequence of infections and vaccine doses). We further accounted for observed individual-169 level variability in anti-SARS-CoV-2 antibody kinetics. Inference was performed in a 170 Bayesian hierarchical framework incorporating uncertainty of the timing of infection events in 171 the absence of information on COVID-19 diagnostic tests. Model details are given in the 172 Supplementary Material (Section S4). Stan model code and minimal testing datasets are 173 available at https://github.com/UEP-HUG/serosuivi 2021 public.

174

Survival analysis. In the second step of the analysis, we evaluated binding antibody levels as a correlate of protection against Omicron BA.1/BA.2 infections during the "exposure period" (Figure 1) using survival analysis methods. The aim was to infer the effect of being above different thresholds of binding antibody levels (as measured by the Roche-S immunoassay) on the hazard of confirmed SARS-CoV-2 infection during the exposure

180 period. We focused on the exposure period from when Omicron BA.1 became dominant 181 (more than 80% of samples on Dec 25th 2021) up to the latest date for which we had access 182 to the state registry of SARS-CoV-2 test results (March 20th 2022). By this date Omicron BA.2 had replaced Omicron BA.1 in Western Switzerland (90% vs. 10% of typed samples, 183 184 Figure 1). We excluded participants with either (a) no serology information after April 1st 2021, or (b) uncertain infection status during the Omicron exposure period due to missing 185 186 data (i.e. missing positive test result and missing self-reported absence of positive tests, details in Supplementary Material Section S1). We used Cox proportional hazards model, 187 188 controlling for age and previous infection status based on our assumptions of the 189 relationship between variables (Supplementary Material Section S5). Given that we used 190 modeled antibody levels during the exposure period based on available serological prior 191 measurements, we excluded participants for whom a boosting event (infection and/or 192 vaccination) occurred between the last serological measurement and the start of the 193 exposure period if the modeled antibody level was below the threshold of interest 194 (Supplementary Material Section S1). Potential informative censoring due to vaccination 195 and/or infection during the Omicron exposure period was adjusted for through inverse 196 probability weighting as implemented in the ipw R package (Wal and Geskus, 2011).

197 **Results**

198 The cohort included in this study was composed of 1'083 adult participants, 55% of whom 199 were female and 91% were younger than 65 years (Table 1). Participants in the cohort had 200 few comorbidities and no immunosuppressive diseases in general. Among participants, 91% 201 had a history of SARS-CoV-2 infection (based on positive tests or anti-N serology as defined in the Supplementary Material Section S1) and 58% were unvaccinated at the time of their 202 most recent serology (range of last serology dates November 16th 2020 - December 17th 203 204 2021, median June 21st 2021). Around half of participants with a history of infection based on a positive anti-N serology did not have any diagnostic screening tests during the actue 205 206 phase of their infection (PCR or RDT) (58%). Most participants in the cohort had only two 207 positive serological tests (56%), and 10% had 4 or more seropositive samples. All event data 208 is presented in Supplementary Figure S2.

Table 1. Participant characteristics.	Characteristics	are given	for the five
encountered infection and vaccination	history.		

Characteristic	N = 1'083 ¹	
Sex		
female	590 (55%)	
male	493 (45%)	
Age (years)		
18-64	988 (91%)	
65+	95 (9%)	
Infection/vaccination status at time of most recent serological test		
infected only	634 (58%)	
vaccinated only	98 (9%)	
infected prior to vaccination	310 (29%)	
infected after vaccination	11 (1%)	
infected prior to vaccination and re- infected after vaccination	30 (3%)	
Virological confirmation among participants with history of infection (N=985)		
Virologically confirmed infection (self- reported or from ARGOS registry)	567 (58%)	
No virological confirmation (anti-N positive serology)	418 (42%)	
Vaccine type among vaccinated participants at time of last serological status (N=449)		
mRNA-1273 (Moderna/US NIAID)	247 (55%)	
mRNA-BNT162b2/Comirnaty (Pfizer/BioNTech)	202 (45%)	
# Positive Roche-S serological samples per participant within this study		
2	603 (55%)	
3	374 (35%)	
4	104 (10%)	
5	1 (<0.1%)	
¹ n (%)		

Antibody trajectories during the longitudinal serology period 211

Serological samples were collected from 1'083 participants between April 2020 and 212 213 December 2021, with follow-up times between first and last visits of up to 20 months following infection and up to 8 months following vaccination (Figure 2a). Over this 214 longitudinal serology period, we did not observe anti-S-based seroreversion for any 215 216 participants (Figure 2b). Antibody levels following vaccination were distributed in the upper 217 range of the immunoassay's dynamic range (Figure 2b, Supplementary Figure S3), with 218 more than one in three samples collected at least 14 days after participant's latest vaccine 219 dose having values above the upper quantification limit of the test (33%, Figure 2d). Anti-N 220 antibody trajectories are shown in Supplementary Figure S4.

221



Figure 2. Anti-S binding antibodies level trajectories. a) Follow-up time distribution (time from participant's first to last serology) for samples collected prior (n = 778) and post (n = 246) vaccination when at least two positive samples were available. Note that participants may have multiple samples prior and post vaccination and may therefore appear in both categories. b) Trajectories for all participants (n = 1'083) by serological sampling date and according to vaccination status. c) Trajectories of pre-vaccination samples by time from virological confirmation when available (n = 442), along with violin plots of antibody levels in discrete arbitrary categories of time post confirmation (0-149, 150-249, 250-449, 450+ days). d) Trajectories post-vaccination by time from latest dose (n = 246). Dashed and dotted lines in panels b, c and d indicate upper quantification limit (2500 U/mL, equivalent to 2960 IU/mL) and threshold for positivity (0.8 U/mL, equivalent to 0.95 IU/mL) of the test, respectively.

222

223 To investigate how infection and vaccination history affects antibody levels, we fit kinetic 224 models to individual-level antibody trajectories. Mean antibody rises were similar among age 225 classes. Rises in anti-S binding antibody levels depended markedly on both infection and 226 vaccination history (Figure 3a, parameter estimates in Supplementary Table S2). The 227 weakest estimated anti-S boost were the ones following infection in unvaccinated 228 individuals, while the strongest boost was estimated following the first vaccine dose in 229 previously infected individuals. Among vaccinated and infected individuals the estimated 230 anti-S boost parameter decreased with the number of vaccine doses. Among uninfected 231 individuals the largest increase in anti-S levels occurred after the second vaccine dose, with 232 similar levels for the first and third doses. Mean antibody half-lives showed less variation 233 among boosting events, ranging from 50 days (95% Crl 30-100) following the second 234 vaccine dose in uninfected 18-64y individuals to 510 days (140-1360) in 65+ individuals with 235 two infections and one vaccine dose (Figure 3b). Estimated antibody half-lives were similar 236 across individuals both infected and vaccinated, regardless of the number of vaccine doses 237 received. In turn, antibodies decayed faster in uninfected individuals following the second 238 dose, as opposed to antibodies mounted with the first and third doses. Both boost level and 239 antibody decay rates had considerable although uncertain individual-level heterogeneity with 240 coefficients of variation of 5.1 (95% Crl 0.2-50.0) and 22.1 (0.3-65.5), respectively. These 241 kinetic parameter estimates along with inference on individual-level variability allowed us to 242 model antibody trajectories for each participant with strong agreement with available 243 serological measurements (Figure 3c, Supplementary Figure S5). 244



245

Survival analysis during the Omicron exposure period 246

In this second part of the analysis, we used survival analysis to evaluate the relationship 247 248 between the projected anti-S binding antibody levels, as described above, and the hazard of 249 infection during the Omicron exposure period (Figure 1). Data on virologically-confirmed 250 infections during the exposure period (positive test or self-reported negative tests only, see 251 Methods) were available for 967 out of the 1'083 participants, of whom we retained 900 with 252 latest serology after April 1st 2021 (Supplementary Figure S1). The subsample included in 253 this survival analysis was composed of 55% of female participants; 92% were younger than 254 65 years; 80% had received at least one vaccine dose prior to the start of the Omicron exposure period (December 25th 2021); and 90% had at least one SARS-CoV-2 infection 255 256 prior to the start of the exposure period (Supplementary Table S3). Out of these 900 participants, 227 had a virologically-confirmed infection during the Omicron exposure period. 257 258

We found that the hazard of having an Omicron BA.1/BA.2 infection for individuals with anti-S binding antibody levels higher than a given arbitrary threshold, compared to those with levels below that threshold, decreased down to a three-fold reduction in hazard at a threshold of 800 IU/mL (hazard ratio, HR 0.30, 95% CI 0.22-0.41), and then plateaued for higher antibody level thresholds (Figure 4a). In sensitivity analyses we found consistent effect sizes across antibody thresholds using logistic regression, as well as using different quantiles of the predicted antibody trajectories (Supplementary Material Section S6).

266

267 We however found that measured antibody-levels do not have the same meaning in terms of 268 correlate of protection whether a participant had a history of infection or not, independently 269 of antibody level (Figure 4b). Similar proportions of Omicron infections were observed 270 among vaccinated participants with no history of infection (and anti-N negative serology) 271 irrespective of their anti-S antibody levels being below or above the 800 IU/mL threshold. 272 Conversely, participants with a history of infection had lower hazard of infection when having 273 antibody levels above the 800 IU/mL threshold, regardless of their vaccination status (Figure 274 4b, bottom row). Thus, for this anti-S antibody levels threshold, effect estimates stratified by 275 infection and vaccination history showed no significant difference in hazard for uninfected 276 (vaccinated) participants (HR 1.05, 0.36-3.05), and a consistent hazard reduction for 277 participants with a history of infection whether they were vaccinated (HR 0.30, 0.07-1.21) or 278 not (HR 0.45, 0.19-1.06), although small sample sizes in some of these categories yielded 279 wide confidence intervals.





perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 4. Omicron BA.1/BA.2 infection survival analysis. a) Cox hazard ratio estimates (dots, error bars give the 95% CI) based on proportional hazard models accounting for age and prior infection status across antibody level thresholds. b) Kaplan-Meier curves of the probability of non-infection by SARS-CoV-2 Omicron BA.1/BA.2 stratified by whether predicted antibody levels during the exposure period were above or below 800 IU/mL, shown for the overall analysis dataset, and stratified by infection and vaccination history. Day 0 corresponds to December 25th 2021, when Omicron BA.1 accounted for more than 80% of infections in the state of Geneva (Figure 1c). For this 800 IU/mL threshold, the overall sample size was of N=562 (flowchart in Supplementary Figure S1), subdivided into N=78 for "No prior infection and vaccinated", N=155 for "Prior infected and non-vaccinated", and N=329 for "Prior infection and vaccinated".

281 Discussion

282 This longitudinal antibody study with follow-up times up to 20 months provided the 283 opportunity to understand long-term anti-SARS-CoV-2 antibody dynamics and to evaluate 284 binding antibody levels from a commercial widely available immunoassay as a correlate of 285 protection against infections during the Omicron BA.1/BA.2 era. Anti-S antibodies persisted up to 20 months after the probable date of infection, with decay dynamics determined by 286 287 infection and vaccination history. Strongest and longest-lasting antibody boosts occurred 288 with vaccine doses following prior infection. Modelled antibody trajectories enabled the 289 evaluation of binding antibody levels as a correlate of protection against Omicron BA.1/BA.2 290 infections, for which we found an overall three-fold reduction in the hazard of reporting a 291 positive test for antibody levels above 800 IU/mL. Hazard reduction was however not 292 observed for non-infected participants, indicating that the validity of anti-S binding antibody 293 levels as correlates of protection for Omicron BA.1/BA.2 depends on infection history.

294

295 This study extends our previous work showing that anti-SARS-CoV-2 spike antibodies 296 remain detectable after 22 months past probable infection as measured with the Roche anti-297 S immunoassay (Perez-Saez et al., 2021). Our kinetic modeling results support previous 298 findings indicating that antibody boost is strongest and longest lasting in vaccinees with a 299 history of infection (Dimeglio et al., 2022a; Eyran et al., 2022; Luo et al., 2021). In contrast 300 with previous findings, we found no significant difference in antibody boosting between age groups and slower decay rates in adults 65 years and older (Gallais et al., 2021: Vanshylla 301 302 et al., 2021). The slower decay rates may be due to age-specific differences in disease 303 severity that we did not account for in these models, thus limiting the comparability of these findings with previous studies due to differences in disease severity profiles. Furthermore, 304 305 we had a small number of participants over 65 years of age in our study and these age-306 stratified results should be interpreted with caution. Finally, our results highlight the strong individual-level variability in antibody dynamics, which has been shown in previous antibody 307 308 kinetic studies (Pelleau et al., 2021; Vanshylla et al., 2021).

310 Survival analysis results on Omicron BA.1/BA.2 infections are in line with previous findings 311 from vaccine trials targeting the ancestral strain and the Alpha variant, showing that binding 312 antibody levels are an informative correlate of protection against SARS-CoV-2 infection (Feng et al., 2021; Gilbert et al., 2022). These trials had found similar effect sizes of around 313 314 five-fold reduction in risk of Alpha infections at anti-S antibody levels of 600 IU/mL (Feng et 315 al., 2021), and a halving of hazard by 10-fold increase in anti-S titers for ancestral strain 316 infections (Gilbert et al., 2022). Moreover our results are in line with available studies on 317 Omicron BA.1/BA.2 subvariants which have also found binding antibody levels to be 318 correlates of protection against infection using in-house immunoassays (Hertz et al., 2022; Zar et al., 2022). On the other hand, we did not find differences in the hazard of having an 319 320 Omicron BA.1/BA.2 infection with anti-S antibody levels below or above a certain threshold 321 in the non-infected vaccinated group, as opposed to results reported for Delta infections 322 (Wei et al., 2021). Notably, this finding is supported by our recent work on neutralization 323 capacity in the Geneva population (Zaballa et al., 2022). Using the same immunoassay as in 324 this study and a cell-free Spike trimer-ACE2 binding-based surrogate neutralization assay 325 (Fenwick et al., 2021), we did not observe any significant correlation between anti-S binding 326 and neutralizing antibody levels against Omicron subvariants in uninfected participants, as 327 opposed to previously infected participants (Zaballa et al., 2022). These results can be 328 linked to growing evidence that hybrid immunity (infection plus vaccination) provides the 329 strongest protection against Omicron subvariant infections (Altarawneh et al. 2022, Zar et al. 330 2022, Golddblatt 2022). This infection history-specificity thus warrants care in the 331 interpretation of binding antibodies as correlates of protection against Omicron sub-lineages. 332 and could be immunoassay-dependent.

333

334 We note that it remains unclear whether these correlate of protection results extend to 335 subsequent Omicron subvariants (BA.4, BA.5, BA.2.75, BQ.1 and othres), which have been 336 found, thanks to specific mutations, to have stronger immune-evasion capacity than the 337 parent BA.1 strain (Cao et al., 2022; Tan et al., 2022). Changes in immune evasion capacity 338 may theoretically, if multiple mutations accumulate on the spike protein, impact the level of 339 binding antibodies at which hazard reduction occurs as well as its effect size. Moreover, our 340 longitudinal serology follow-up was conducted before the circulation of the Omicron lineage 341 in Geneva. The interpretation of anti-S antibody levels measured with this immunoassay 342 following Omicron infections might need to be revisited in the light of evidence of reduced 343 test sensitivity towards antibodies targeting the Omicron Spike protein (Springer et al., 344 2022).

346 This study has several limitations. Firstly, we only used the Roche Elecsys assay, which 347 measures total anti-S antibodies (IgA/M/G), whose levels may correlate differently with 348 overall immune function following infection or vaccination: other immunoassays may have different antibody binding characteristics. Secondly, analyses in the 65+ subgroup are 349 350 limited by the small number of participants. Thirdly, our survival analysis to assess correlates 351 of protection was based on modeled antibody trajectories, and not on measurements at 352 defined time points as done in studies available from vaccine trails (Gilbert et al., 2022). 353 Although modeled trajectories matched well antibody participant-level measurements, the 354 survival analysis results are subject to modeling uncertainty. While sensitivity analysis using 355 the 2.5% and 97.5% prediction quantiles vielded gualitatively similar correlate of protection results, other sources of modeling uncertainty cannot be excluded. Fourthly, a large 356 proportion of virologically-confirmed infections (44%, 101/227) were self-reported as 357 358 opposed to the other 56%, which were directly extracted from the state COVID-19 test 359 registry (ARGOS). Reassuringly, of the 1'083 participants in our longitudinal sample for 360 whom tests in the registry were available, self-reported positive tests with matching dates 361 were reported in 82% (491/599) of cases, thus suggesting a reasonable sensitivity of self-362 reporting. Finally, both Omicron BA.1 and BA.2 subvariants circulated in the canton of 363 Geneva during the study exposure period and sequencing information on infection was not 364 available, thus precluding a differential correlate of protection analysis for both subvariants. 365

366 Overall, this study extends findings against previous SARS-CoV-2 variants showing that 367 anti-S binding antibody levels are a valid correlate of protection against Omicron BA.1/BA.2 368 infections. Importantly, we found that the validity of antibody levels as correlate of protection 369 depends on infection history as quantified with the immunoassay used in this study. Our 370 results highlight the imperfect nature of protection after vaccination and/or infection. Even 371 with perfect knowledge of infection and vaccination histories, inference about population-372 level immunity continues to pose challenges. Future studies may benefit from the modeling 373 framework developed in this study to leverage longitudinal measurements to epidemiological 374 outcomes. Taken together, these conclusions motivate further investigation of how immune 375 landscape and immunoassay characteristics determine the interpretation of serological 376 surveys into population-levels of protection to inform public health decisions.

377 Acknowledgements

378 We thank Aglaé Tardin and the team of General Directorate of Health of Geneva for giving 379 us access to the ARGOS state registry, and the Hôpital de La Tour and the Clinique de

Carouge for allowing us to use their premises for the recruitment of participants. We are deeply grateful to all the participants, without whom this study would not have been possible.

382 Funding

- 383 This study was funded by the Private Foundation of the Geneva University Hospitals and the
- 384 General Directorate of Health of the canton of Geneva. The funders had no role in study
- 385 design, data collection and analysis, decision to publish, or preparation of the manuscript.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

386 **References**

- Altarawneh, H.N., Chemaitelly, H., Ayoub, H.H., Tang, P., Hasan, M.R., Yassine, H.M., Al-Khatib,
 H.A., Smatti, M.K., Coyle, P., Al-Kanaani, Z. and Al-Kuwari, E., 2022. Effects of previous
 infection and vaccination on symptomatic omicron infections. *New England Journal of Medicine*, 387(1), pp.21-34.
- Baysson, H., Pennacchio, F., Wisniak, A., Zaballa, M.E., Pullen, N., Collombet, P., Lorthe, E., Joost,
 S., Balavoine, J.-F., Bachmann, D., Azman, A., Pittet, D., Chappuis, F., Kherad, O., Kaiser,
 L., Guessous, I., Stringhini, S., 2022. Specchio-COVID19 cohort study: a longitudinal followup of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland. BMJ Open
 12, e055515. https://doi.org/10.1136/bmjopen-2021-055515
- Bergeri, I., Whelan, M., Ware, H., Subissi, L., Nardone, A., Lewis, H.C., Li, Z., Ma, X., Valenciano, M.,
 Cheng, B., Ariqi, L.A., Rashidian, A., Okeibunor, J., Azim, T., Wijesinghe, P., Le, L.-V.,
 Vaughan, A., Pebody, R., Vicari, A., Yan, T., Yanes-Lane, M., Cao, C., Clifton, D.A., Cheng,
 M.P., Papenburg, J., Buckeridge, D., Bobrovitz, N., Arora, R.K., Kerkhove, M.D.V., Group,
 the U.S.C., 2022. Global SARS-CoV-2 seroprevalence: a systematic review and metaanalysis of standardized population-based studies from Jan 2020-May 2022.
 https://doi.org/10.1101/2021.12.14.21267791
- 403 Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., Yu, Y., 404 Wang, P., Zhang, Z., Liu, P., An, R., Hao, X., Wang, Yao, Wang, J., Feng, R., Sun, H., Zhao, 405 L., Zhang, W., Zhao, D., Zheng, J., Yu, L., Li, C., Zhang, N., Wang, R., Niu, X., Yang, S., 406 Song, X., Chai, Y., Hu, Y., Shi, Y., Zheng, L., Li, Z., Gu, Q., Shao, F., Huang, W., Jin, R., 407 Shen, Z., Wang, Youchun, Wang, X., Xiao, J., Xie, X.S., 2022. BA.2.12.1, BA.4 and BA.5 408 antibodies elicited bv Omicron infection. 608. escape Nature 593-602. 409 https://doi.org/10.1038/s41586-022-04980-y
- Dimeglio, C., Herin, F., Da-Silva, I., Porcheron, M., Martin-Blondel, G., Chapuy-Regaud, S., Izopet, J.,
 2022a. Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
 Antibody Kinetics and Protection Duration. Clin Infect Dis 75, e924–e925.
 https://doi.org/10.1093/cid/ciab984
- 414Dimeglio, C., Herin, F., Martin-Blondel, G., Miedougé, M., Izopet, J., 2022b. Antibody titers and415protection against a SARS-CoV-2 infection. Journal of Infection 84, 248–288.416https://doi.org/10.1016/j.jinf.2021.09.013
- 417 Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P.B., Siber, G.R., Dull, P.,
 418 Plotkin, S.A., 2021. Evidence for antibody as a protective correlate for COVID-19 vaccines.
 419 Vaccine 39, 4423–4428. https://doi.org/10.1016/j.vaccine.2021.05.063
- Eyran, T., Vaisman-Mentesh, A., Taussig, D., Dror, Y., Aizik, L., Kigel, A., Rosenstein, S., Bahar, Y.,
 Ini, D., Tur-Kaspa, R., Kournos, T., Marcoviciu, D., Dicker, D., Wine, Y., 2022. Longitudinal
 kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months. PLoS Pathog
 18, e1010569. https://doi.org/10.1371/journal.ppat.1010569
- Feng, S., Phillips, D.J., White, T., Sayal, H., Aley, P.K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S.C.,
 Hirsch, I., Humphries, H.E., Jepson, B., Kelly, E.J., Plested, E., Shoemaker, K., Thomas,
 K.M., Vekemans, J., Villafana, T.L., Lambe, T., Pollard, A.J., Voysey, M., 2021. Correlates of
 protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 27, 2032–
 2040. https://doi.org/10.1038/s41591-021-01540-1
- 429 Fenwick, C., Turelli, P., Pellaton, C., Farina, A., Campos, J., Raclot, C., Pojer, F., Cagno, V., Nusslé, 430 S.G., D'Acremont, V., Fehr, J., Puhan, M., Pantaleo, G., Trono, D., 2021. A high-throughput 431 cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-432 convalescent 19 plasma. Sci Transl Med 13. eabi8452. 433 https://doi.org/10.1126/scitranslmed.abi8452
- Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M.-J., Bayer, S., Solis, M., Laugel,
 E., Reix, N., Schneider, A., Glady, L., Panaget, B., Collongues, N., Partisani, M., Lessinger,
 J.-M., Fontanet, A., Rey, D., Hansmann, Y., Kling-Pillitteri, L., Schwartz, O., Sèze, J.D.,
 Meyer, N., Gonzalez, M., Schmidt-Mutter, C., Fafi-Kremer, S., 2021. Evolution of antibody
 responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. eBioMedicine
 https://doi.org/10.1016/j.ebiom.2021.103561

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 440 Genecand, C., Mongin, D., Koegler, F., Lebowitz, D., Regard, S., Falcone, J.-L., Nehme, M., Braillard, 441 O., Grira, M., Joubert, D., Chopard, P., Delaporte, E., Stirnemann, J., Guessous, I., Tardin, 442 A., Courvoisier, D.S., 2021, Cohort profile: Actionable Register of Geneva Outpatients and 443 SARS-CoV-2 (ARGOS). BMJ e048946. inpatients with Open 11. 444 https://doi.org/10.1136/bmjopen-2021-048946
- 445 Gilbert, P.B., Montefiori, D.C., McDermott, A.B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., 446 Houchens, C.R., Martins, K., Jayashankar, L., Castellino, F., Flach, B., Lin, B.C., O'Connell, 447 S., McDanal, C., Eaton, A., Sarzotti-Kelsoe, M., Lu, Y., Yu, C., Borate, B., van der Laan, 448 L.W.P., Hejazi, N.S., Huynh, C., Miller, J., El Sahly, H.M., Baden, L.R., Baron, M., De La Cruz, L., Gay, C., Kalams, S., Kelley, C.F., Andrasik, M.P., Kublin, J.G., Corey, L., Neuzil, 449 450 K.M., Carpp, L.N., Pajon, R., Follmann, D., Donis, R.O., Koup, R.A., Immune Assays Team, 451 Moderna, Inc. Team. Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy 452 (COVE) Team, UNITED STATES GOVERNMENT (USG)/COVPN BIOSTATISTICS TEAM, 453 2022. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. 454 Science 375, 43-50. https://doi.org/10.1126/science.abm3425
- Goldblatt, D., Fiore-Gartland, A., Johnson, M., Hunt, A., Bengt, C., Zavadska, D., Snipe, H.D., Brown,
 J.S., Workman, L., Zar, H.J., Montefiori, D., Shen, X., Dull, P., Plotkin, S., Siber, G.,
 Ambrosino, D., 2022. Towards a population-based threshold of protection for COVID-19
 vaccines. Vaccine 40, 306–315. https://doi.org/10.1016/j.vaccine.2021.12.006
- 459 Goldblatt, D., 2022. SARS-CoV-2: from herd immunity to hybrid immunity. Nature Reviews
- 460 *Immunology*, *22*(6), pp.333-334.
- 461 Hertz, T., Levy, S., Ostrovsky, D., Oppenheimer, H., Zismanov, S., Kuzmina, A., Friedman, L.M., 462 Trifkovic, S., Brice, D., Chun-Yang, L., Shemer-Avni, Y., Cohen-Lahav, M., Amichay, D., 463 Keren-Naus, A., Voloshin, O., Weber, G., Najjar-Debbiny, R., Chazan, B., McGargill, M.A., 464 Webby, R., Chowers, M., Novack, L., Novack, V., Taube, R., Nesher, L., Weinstein, O., 2022. 465 Correlates of protection for booster doses of the BNT162b2 vaccine. 466 https://doi.org/10.1101/2022.07.16.22277626
- Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao, K., Kent,
 S.J., Triccas, J.A., Davenport, M.P., 2021. Neutralizing antibody levels are highly predictive of
 immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27, 1205–1211. https://
 doi.org/10.1038/s41591-021-01377-8
- 471 Krammer, F., 2021. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med
 472 27, 1147–1148. https://doi.org/10.1038/s41591-021-01432-4
- 473 L'Huillier, A.G., Meyer, B., Andrey, D.O., Arm-Vernez, I., Baggio, S., Didierlaurent, A., Eberhardt, 474 C.S., Eckerle, I., Grasset-Salomon, C., Huttner, A., Posfay-Barbe, K.M., Royo, I.S., Pralong, 475 J.A., Vuilleumier, N., Yerly, S., Siegrist, C.-A., Kaiser, L., 2021. Antibody persistence in the 476 first 6 months following SARS-CoV-2 infection among hospital workers: a prospective 477 longitudinal studv. Clinical Microbioloav and Infection 784.e1-784.e8. 27. 478 https://doi.org/10.1016/j.cmi.2021.01.005
- 479 Luo, Y.R., Chakraborty, I., Yun, C., Wu, A.H.B., Lynch, K.L., 2021. Kinetics of Severe Acute 480 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Avidity Maturation and 481 Association with Disease Severity. Clin Infect Dis 73, e3095-e3097. 482 https://doi.org/10.1093/cid/ciaa1389
- Perry J, Osman S, Wright J, Richard-Greenblatt M, Buchan SA, Sadarangani M, et al. Does a
 humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS One. 2022;17:
- 484 numbral correlate of protection exist for SARS-Cov-2? A systematic review. PLoS One. 2022,17 485 e0266852.
- Pelleau, S., Woudenberg, T., Rosado, J., Donnadieu, F., Garcia, L., Obadia, T., Gardais, S.,
 Elgharbawy, Y., Velay, A., Gonzalez, M., Nizou, J.Y., Khelil, N., Zannis, K., Cockram, C.,
 Merkling, S.H., Meola, A., Kerneis, S., Terrier, B., de Seze, J., Planas, D., Schwartz, O.,
 Dejardin, F., Petres, S., von Platen, C., Pellerin, S.F., Arowas, L., de Facci, L.P., Duffy, D.,
- 490 Cheallaigh, C.N., Dunne, J., Conlon, N., Townsend, L., Duong, V., Auerswald, H., Pinaud, L.,
- 491 Tondeur, L., Backovic, M., Hoen, B., Fontanet, A., Mueller, I., Fafi-Kremer, S., Bruel, T., White,
- 492 M., 2021. Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response 493 and Serological Estimation of Time Since Infection. J Infect Dis 224, 1489–1499.
- 494 https://doi.org/10.1093/infdis/jiab375

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 495 Peluso, M.J., Takahashi, S., Hakim, J., Kelly, J.D., Torres, L., Iyer, N.S., Turcios, K., Janson, O., 496 Munter, S.E., Thanh, C., Donatelli, J., Nixon, C.C., Hoh, R., Tai, V., Fehrman, E.A., 497 Hernandez, Y., Spinelli, M.A., Gandhi, M., Palafox, M.-A., Vallari, A., Rodgers, M.A., Prostko, 498 J., Hackett, J., Trinh, L., Wrin, T., Petropoulos, C.J., Chiu, C.Y., Norris, P.J., DiGermanio, C., 499 Stone, M., Busch, M.P., Elledge, S.K., Zhou, X.X., Wells, J.A., Shu, A., Kurtz, T.W., Pak, J.E., 500 Wu, W., Burbelo, P.D., Cohen, J.I., Rutishauser, R.L., Martin, J.N., Deeks, S.G., Henrich, 501 T.J., Rodriguez-Barraquer, I., Greenhouse, B., 2021. SARS-CoV-2 antibody magnitude and 502 detectability are driven by disease severity, timing, and assay. Sci Adv 7, eabh3409. 503 https://doi.org/10.1126/sciadv.abh3409
- Perez-Saez, J., Zaballa, M.-E., Yerly, S., Andrey, D.O., Meyer, B., Eckerle, I., Balavoine, J.-F., Chappuis, F., Pittet, D., Trono, D., Kherad, O., Vuilleumier, N., Kaiser, L., Guessous, I., Stringhini, S., Azman, A.S., 2021. Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2021.06.040
- Springer, D.N., Perkmann, T., Jani, C.M., Mucher, P., Prüger, K., Marculescu, R., Reuberger, E.,
 Camp, J.V., Graninger, M., Borsodi, C., Deutsch, J., Lammel, O., Aberle, S.W., PuchhammerStöckl, E., Haslacher, H., Höltl, E., Aberle, J.H., Stiasny, K., Weseslindtner, L., 2022.
 Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection
 with the SARS-CoV-2 Omicron Variant. Microbiology Spectrum 10, e02129-22. https://doi.org/
 10.1128/spectrum.02129-22
- Stringhini, S., Wisniak, A., Piumatti, G., Azman, A.S., Lauer, S.A., Baysson, H., De Ridder, D.,
 Petrovic, D., Schrempft, S., Marcus, K., Yerly, S., Arm Vernez, I., Keiser, O., Hurst, S.,
 Posfay-Barbe, K.M., Trono, D., Pittet, D., Gétaz, L., Chappuis, F., Eckerle, I., Vuilleumier, N.,
 Meyer, B., Flahault, A., Kaiser, L., Guessous, I., 2020. Seroprevalence of anti-SARS-CoV-2
 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet
 396, 313–319. https://doi.org/10.1016/S0140-6736(20)31304-0
- Stringhini, S., Zaballa, M.-E., Perez-Saez, J., Pullen, N., de Mestral, C., Picazio, A., Pennacchio, F.,
 Wisniak, A., Richard, A., Baysson, H., others, 2021a. Seroprevalence of anti-SARS-CoV-2
 antibodies after the second pandemic peak. The Lancet. Infectious Diseases 21, 600–601.
- 524 Stringhini, S., Zaballa, M.-E., Pullen, N., de Mestral, C., Perez-Saez, J., Dumont, R., Picazio, A., 525 Pennacchio, F., Dibner, Y., Yerly, S., Baysson, H., Vuilleumier, N., Balavoine, J.-F., 526 Bachmann, D., Trono, D., Pittet, D., Chappuis, F., Kherad, O., Kaiser, L., Azman, A.S., 527 Guessous, I., 2021b. Large variation in anti-SARS-CoV-2 antibody prevalence among 528 workers in Geneva, Switzerland. Nat Commun 3455. essential 12, 529 https://doi.org/10.1038/s41467-021-23796-4
- Tan, C.-W., Lim, B.-L., Young, B.E., Yeoh, A.Y.-Y., Yung, C.-F., Yap, W.-C., Althaus, T., Chia, W.-N.,
 Zhu, F., Lye, D.C., Wang, L.-F., 2022. Comparative neutralisation profile of SARS-CoV-2
 omicron subvariants BA.2.75 and BA.5. The Lancet Microbe 0. https://doi.org/10.1016/S26665247(22)00220-8
- Theel, E.S., Slev, P., Wheeler, S., Couturier, M.R., Wong, S.J., Kadkhoda, K., 2020. The Role of
 Antibody Testing for SARS-CoV-2: Is There One? J Clin Microbiol 58, e00797-20.
 https://doi.org/10.1128/JCM.00797-20
- Vanshylla, K., Di Cristanziano, V., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell,
 H., Schlotz, M., Ercanoglu, M.S., Stumpf, R., Mayer, P., Zehner, M., Heger, E., Johannis, W.,
 Horn, C., Suárez, I., Jung, N., Salomon, S., Eberhardt, K.A., Gathof, B., Fätkenheuer, G.,
 Pfeifer, N., Eggeling, R., Augustin, M., Lehmann, C., Klein, F., 2021. Kinetics and correlates
 of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell Host Microbe
 29, 917-929.e4. https://doi.org/10.1016/j.chom.2021.04.015
- 543 Wal, W.M. van der, Geskus, R.B., 2011. ipw: An R Package for Inverse Probability Weighting. Journal 544 of Statistical Software 43, 1–23. https://doi.org/10.18637/jss.v043.i13
- Wei, J., Stoesser, N., Matthews, P.C., Ayoubkhani, D., Studley, R., Bell, I., Bell, J.I., Newton, J.N.,
 Farrar, J., Diamond, I., Rourke, E., Howarth, A., Marsden, B.D., Hoosdally, S., Jones, E.Y.,
 Stuart, D.I., Crook, D.W., Peto, T.E.A., Pouwels, K.B., Eyre, D.W., Walker, A.S., COVID-19
 Infection Survey team, 2021. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults
 from the general population of the United Kingdom. Nat Microbiol 6, 1140–1149.
 https://doi.org/10.1038/s41564-021-00947-3

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- Zaballa, M.-E., Perez-Saez, J., Mestral, C. de, Pullen, N., Lamour, J., Turelli, P., Raclot, C., Baysson,
 H., Pennacchio, F., Villers, J., Duc, J., Richard, V., Dumont, R., Semaani, C., Loizeau, A.J.,
 Graindorge, C., Lorthe, E., Balavoine, J.-F., Pittet, D., Schibler, M., Vuilleumier, N., Chappuis,
 F., Kherad, O., Azman, A.S., Posfay-Barbe, K.M., Kaiser, L., Trono, D., Stringhini, S.,
 Guessous, I., Group, the S.-C. study, 2022. Seroprevalence of anti-SARS-CoV-2 antibodies
 and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva,
 Switzerland. https://doi.org/10.1101/2022.07.27.22278126
- Zar, H.J., MacGinty, R., Workman, L., Botha, M., Johnson, M., Hunt, A., Burd, T., Nicol, M.P.,
 Flasche, S., Quilty, B.J., Goldblatt, D., 2022. Natural and hybrid immunity following four
 COVID-19 waves: A prospective cohort study of mothers in South Africa. eClinicalMedicine
 53, 101655. https://doi.org/10.1016/j.eclinm.2022.101655
- 562